Rufloxacin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584714

CAS#: 101363-10-4

Description: Rufloxacin belongs to the class of fluoroquinolones that act mainly as specific inhibitors of bacterial Topoisomerase II. These drugs are widely known to be involved in various diseases ranging from cutaneous reactions to aging.

Chemical Structure

img
Rufloxacin
CAS# 101363-10-4
Instruction

Theoretical Analysis

MedKoo Cat#: 584714
Name: Rufloxacin
CAS#: 101363-10-4
Chemical Formula: C17H18FN3O3S
Exact Mass: 363.11
Molecular Weight: 363.407
Elemental Analysis: C, 56.19; H, 4.99; F, 5.23; N, 11.56; O, 13.21; S, 8.82

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Rufloxacin; MF 934

IUPAC/Chemical Name: 9-Fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid

InChi Key: NJCJBUHJQLFDSW-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)

SMILES Code: O=C(C(C1=O)=CN2CCSC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 363.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gismondo MR, Drago L, Lombardi A, Fassina C, Cesana M. Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ-free mice model. Chemotherapy. 1995 Jul-Aug;41(4):281-8. PubMed PMID: 7555209.

2: Lazzaroni M, Imbimbo BP, Bargiggia S, Sangaletti O, Dal Bo L, Broccali G, Bianchi Porro G. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. Antimicrob Agents Chemother. 1993 Oct;37(10):2212-6. PubMed PMID: 8257146; PubMed Central PMCID: PMC192252.

3: Gu LY, Lin WW, Lu H, Chen XY, Ge ZZ, Li XB. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter. 2011 Aug;16(4):284-8. doi: 10.1111/j.1523-5378.2011.00848.x. PubMed PMID: 21762267.

4: Catalfo A, Scifo C, Stella S, Belvedere A, Renis M, De Guidi G. Rufloxacin induced photosensitization in bio-models of increasing complexity. Photochem Photobiol Sci. 2005 Mar;4(3):304-14. Epub 2005 Feb 2. PubMed PMID: 15739000.

5: Jardin A, Cesana M. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group. Antimicrob Agents Chemother. 1995 Jan;39(1):215-20. PubMed PMID: 7695309; PubMed Central PMCID: PMC162511.

6: Carlucci G, Mazzeo P, Palumbo G. Simultaneous determination of rufloxacin, fenbufen and felbinac in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Jul 12;682(2):315-9. PubMed PMID: 8844425.

7: Wise R, Andrews JM, Matthews R, Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 1992 Jun;29(6):649-60. PubMed PMID: 1324239.

8: Del Río G, Dalet F, Aguilar L, Caffaratti J, Dal-Ré R. Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. Antimicrob Agents Chemother. 1996 Feb;40(2):408-12. PubMed PMID: 8834888; PubMed Central PMCID: PMC163124.

9: Cuffini AM, Tullio V, Allocco A, Paizis G, De Leo C, Carlone NA. Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo and in-vivo results. J Antimicrob Chemother. 1994 Oct;34(4):545-53. PubMed PMID: 7868406.

10: Catalfo A, Calandra ML, Renis M, Serrentino ME, De Guidi G. Rufloxacin-induced photosensitization in yeast. Photochem Photobiol Sci. 2007 Feb;6(2):181-9. Epub 2007 Jan 2. PubMed PMID: 17277842.

11: Klietmann W, Cesana M, Rondel RK, Focht J. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 1993 Nov;37(11):2298-306. PubMed PMID: 8285609; PubMed Central PMCID: PMC192382.

12: Savoca G, Raber M, Lissiani A, Plaino F, Ciampalini S, Buttazzi L, Belgrano E. Comparison of single preoperative oral rufloxacin versus perioperative ciprofloxacin as prophylactic agents in transurethral surgery. Arch Ital Urol Androl. 2000 Apr;72(1):15-20. Review. PubMed PMID: 10875161.

13: Bauer TM, Follo A, Navasa M, Vila J, Planas R, Clemente G, Vargas V, Bory F, Vaquer P, Rodés J. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci. 2002 Jun;47(6):1356-61. PubMed PMID: 12064813.

14: Aguilar L, Balcabao IP, Salvá P, Martín M, Costa J, Prieto J, Dal-ré R. Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers. Antimicrob Agents Chemother. 1996 Jan;40(1):17-21. PubMed PMID: 8787872; PubMed Central PMCID: PMC163049.

15: Moretti MV, Pauluzzi S, Cesana M. Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges. Antimicrob Agents Chemother. 2000 Jan;44(1):73-7. PubMed PMID: 10602726; PubMed Central PMCID: PMC89631.

16: Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol. 1991 Apr;29(4):133-8. PubMed PMID: 2071262.

17: Privitera G, Nicastro G, Imbimbo BP, Cesana M, Visconti M, Lombardi F, Tagliabue G, Faleschini E, Colturani F, Franzini P, et al. Biliary excretion of rufloxacin in humans. Antimicrob Agents Chemother. 1993 Dec;37(12):2545-9. PubMed PMID: 8109915; PubMed Central PMCID: PMC192734.

18: Bach D, van den Berg-Segers A, Hübner A, van Breukelen G, Cesana M, Plétan Y. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. J Urol. 1995 Jul;154(1):19-24. PubMed PMID: 7776420.

19: Condorelli G, De Guidi G, Giuffrida S, Sortino S, Chillemi R, Sciuto S. Molecular mechanisms of photosensitization induced by drugs. XII. Photochemistry and photosensitization of rufloxacin: an unusual photodegradation path for the antibacterials containing a fluoroquinolone-like chromophore. Photochem Photobiol. 1999 Sep;70(3):280-6. PubMed PMID: 10483356.

20: Yu IL, Chung SJ, Lee MH, Shim CK. Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. J Pharm Sci. 1997 May;86(5):550-3. PubMed PMID: 9145377.